Mixed cell populations for tissue repair and separation technique for cell processing

Abstract

The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.

1. A method of tissue repair or regeneration comprising administering a patient in need thereof an isolated cell composition comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage, wherein the cell composition is characterizes as:
 a) being at least 80% viable; 
 b) containing about 5-75% viable CD90 +  cells with the remaining cells in said composition being CD45 + ; 
 c) containing less than 2 μg/ml of bovine serum albumin; 
 d) containing less than 1 μg/ml of a enzymatically active harvest reagent; and 
 e) being substantially free of mycoplasm, endotoxin, and microbial contamination. 
 
     
     
       2. The method of  claim 1 , wherein said cell composition is in a pharmaceutical-grade electrolyte solution suitable for human administration. 
     
     
       3. The method of  claim 1 , wherein said cell composition produces less than 10 pg/mL per 24 hour period per 10 5  cells of one or more pro-inflammatory cytokines. 
     
     
       4. The method of  claim 1 , wherein said cells express indoleamine 2,3,-dioxygenase or PD-L1. 
     
     
       5. The method of  claim 1 , wherein said at least 10% of said CD90 +  cells co-express CD15. 
     
     
       6. The method of  claim 1 , wherein said CD45 +  cells co-express CD14, CD34 or VEGFR1. 
     
     
       7. The method of  claim 1 , wherein said cell composition is further characterized as f) being substantially free of horse serum and/or fetal bovine serum. 
     
     
       8. The method of  claim 1 , wherein the total number of viable cells in said composition is 35 million to 300 million. 
     
     
       9. The method of  claim 8 , wherein said cells are in a volume less than 15 milliliters. 
     
     
       10. The method of  claim 8 , wherein said cells are in a volume less than 10 milliliters. 
     
     
       11. The method of  claim 8 , wherein said cells are in a volume less than 7.5 milliliters. 
     
     
       12. The method of  claim 1 , wherein said tissue repair and regeneration is bone repair and regeneration. 
     
     
       13. The method of  claim 1 , wherein said tissue repair involves inducing angiogenesis. 
     
     
       14. The method of  claim 1 , wherein said composition modulates the immune response or the inflammatory response. 
     
     
       15. The method of  claim 1 , wherein said tissue repair and regeneration is cardiac tissue repair and regeneration.